Related Topics:
Contact Us
Home | Multisystem Search | Topic Searches | System Data Searches | About the Data | Data Downloads | Widgets | Services | Mobile | Other Datasets
 
Facility ID: 90505BCHMN3132K

Facility Name and Address:
 BACHEM AMERICAS INC.
3132 KASHIWA ST
TORRANCE, CA 90505

Parent Company: NA

Industry: Pharmaceutical Preparation Manufacturing (325412)
Chemical: N,N-Dimethylformamide

Reports:
View TRI Facility profile report for this facility
View TRI Form R submissions by this facility


*You can navigate within the map with your mouse.

Production Related Waste Management for Selected Chemical


Show P2 data for other chemicals at this facility:
lchemid=0000068122
Chart Options1:



    Waste Management Comparison -



Find more P2 activities for this industry and chemical
Display facility comparison report for this industry and chemical


Pollution Prevention Activities for Selected Chemical

Reporting Year Section 8.10: Newly Implemented Source Reduction Activity Section 8.10: Methods to Identify Activity Section 8.11: Optional Pollution Prevention Information*
2019 Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction.
Barriers: B5-Barriers to P2 B5 - Specific regulatory/permit burdens.

Barriers to P2: B5 - Specific regulatory/permit burdens. - The current process is approved by our customers and regulated by the FDA.

Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - The current process is approved by our customers and regulated by the FDA.
2018 Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction.
Barriers: B5-Barriers to P2 B5 - Specific regulatory/permit burdens.

Barriers to P2: B5 - Specific regulatory/permit burdens. - The current process is approved by our customers and regulated by the FDA.

Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - The current process is approved by our customers and regulated by the FDA.
2017 Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction.
Barriers: B5-Barriers to P2 B5 - Specific regulatory/permit burdens.

Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - The current process is approved and regulated by the FDA.

Barriers to P2: B5 - Specific regulatory/permit burdens. - The current process is approved and regulated by the FDA.
2016 Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction.
Barriers: B5-Barriers to P2 B5 - Specific regulatory/permit burdens.

Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - The current process is approved and regulated by the FDA.

Barriers to P2: B5 - Specific regulatory/permit burdens. - The current process is approved and regulated by the FDA.
2015 Barriers: B3-Barriers to P2 B3 - Concern that product quality may decline as a result of source reduction.
Barriers: B5-Barriers to P2 B5 - Specific regulatory/permit burdens.

Barriers to P2: B3 - Concern that product quality may decline as a result of source reduction. - The current process is approved and regulated by the FDA.

Barriers to P2: B5 - Specific regulatory/permit burdens. - The current process is approved and regulated by the FDA.
2014 Barriers: B5-Barriers to P2 B5 - Specific regulatory/permit burdens.

Barriers to P2: B5 - Specific regulatory/permit burdens. - due to the fact that Bachem Americas, Inc. is regulated by the FDA.
2013 Other Barriers to Source Reduction - Concern that product quality may decline as a result of source reduction and specific regulatory/permit burdens due to the fact that Bachem is regulated by the FDA.
2012 Other Barriers to Source Reduction - Concern that product quality may decline as a result of source reduction and Specific regulatory/permit burdens due to fact that Bachem is regulated by the FDA
2011 Barriers to P2 - Bachem is regulated by the FDA.
2009 Barriers to P2 - This facility is regulated by the food and drug admininstration (Fda). Any changes in process activities including source reduction and recycling must be approved in advance by the fda.
2008 Barriers to P2 - This facility is regulated by the food and drug admininstration (Fda). Any changes in process activities including source reduction and recycling must be approved in advance by the fda.
2001 Source Reduction:: W13: Improved maintenance scheduling, recordkeeping, or procedures

Source Reduction:: W19: Other changes in operating practices

Source Reduction:: W58: Other process modifications
Methods to Identify SR Opportunities: T03: Materials balance audits
Methods to Identify SR Opportunities: T04: Participative team management
Methods to Identify SR Opportunities: T03: Materials balance audits
Methods to Identify SR Opportunities: T04: Participative team management
Methods to Identify SR Opportunities: T04: Participative team management
2000 Source Reduction:: W19: Other changes in operating practices
Methods to Identify SR Opportunities: T04: Participative team management
*Classifications of Optional Pollution Prevention Information shown in brackets are provided by EPA.